Clinical Trial Update: A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Linvoseltamab in adults with relapsed or refractory systemic light-chain (AL) amyloidosis, currently recruiting in Phase 1/Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Light-chain Amyloidosis

Drugs mentioned

• Linvoseltamab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis | Phase 1, Phase 2 | Status: RECRUITING